Safety of Single-Dose Primaquine in G6PD-Deficient and G6PD-Normal Males in Mali Without Malaria: An Open-Label, Phase 1, Dose-Adjustment Trial
Ingrid Chen(University of California, San Francisco), Alassane Dicko(University of Bamako), Teun Bousema(Radboud University Nijmegen), Joelle Brown(University of California, San Francisco), Roly Gosling(University of California, San Francisco), Mikko Niemi(University of Helsinki), Moussa Djimdé(Université des Sciences, des Techniques et des Technologies de Bamako), Helmi Pett(University of Helsinki), Bryan Greenhouse(San Francisco General Hospital), Maxwell Murphy(University of California, San Francisco), Kalifa Diarra, Jimee Hwang(Centers for Disease Control and Prevention), Almahamoudou Mahamar(Centre National de la Recherche Scientifique), Daouda Koné, Sekouba Keita, Halimatou Diawara(Université des Sciences, des Techniques et des Technologies de Bamako), Koualy Sanogo, Mohamed Kéïta(University of Bamako)
Cited by 27
Related Papers
Targeting Asymptomatic Malaria Infections: Active Surveillance in Control and Elimination
|PLoS Medicine|2013|356
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
|The Lancet|2024|345
Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
|The Journal of Infectious Diseases|2021|332
Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms
|Cell Reports|2021|266
FLASH: a next-generation CRISPR diagnostic for multiplexed detection of antimicrobial resistance sequences
|Nucleic Acids Research|2019|262